AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: A safe and effective adjunctive therapy
Authors: Kapadia, SR Bajzer, CT Ziada, KM Bhatt, DL Wazni, OM Silver, MJ Beven, EG Ouriel, K Yadav, JS
Citation: Sr. Kapadia et al., Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: A safe and effective adjunctive therapy, STROKE, 32(10), 2001, pp. 2328-2332
Incremental prognostic value of elevated baseline C-reactive protein amongestablished markers of risk in percutaneous coronary intervention
Authors: Chew, DP Bhatt, DL Robbins, MA Penn, MS Schneider, JP Lauer, MS Topol, EJ Ellis, SG
Citation: Dp. Chew et al., Incremental prognostic value of elevated baseline C-reactive protein amongestablished markers of risk in percutaneous coronary intervention, CIRCULATION, 104(9), 2001, pp. 992-997
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes
Authors: Roffi, M Chew, DP Mukherjee, D Bhatt, DL White, JA Heeschen, C Hamm, CW Moliterno, DJ Califf, RA White, HD Kleiman, NS Theroux, P Topol, EJ
Citation: M. Roffi et al., Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes, CIRCULATION, 104(23), 2001, pp. 2767-2771
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acutecoronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Authors: Lauer, MA Houghtaling, PL Peterson, JG Granger, CB Bhatt, DL Sapp, SK Simoons, ML Harrington, RA Topol, EJ Lincoff, AM
Citation: Ma. Lauer et al., Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acutecoronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 104(23), 2001, pp. 2772-2777
Defining the optimal activated clotting times during percutaneous coronaryintervention: Aggregate results from 6 randomized, controlled trials - Response
Authors: Chew, DP Bhatt, DL Lincoff, AM Moliterno, DJ Brener, SJ Wolski, KE Topol, EJ
Citation: Dp. Chew et al., Defining the optimal activated clotting times during percutaneous coronaryintervention: Aggregate results from 6 randomized, controlled trials - Response, CIRCULATION, 104(22), 2001, pp. E124-E124
Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: An explanation? Response
Authors: Chew, DP Bhatt, DL Topol, EJ Sapp, S
Citation: Dp. Chew et al., Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: An explanation? Response, CIRCULATION, 104(20), 2001, pp. E109-E109
Optimal activated clotting time during percutaneous coronary intervention - Response
Authors: Chew, DP Bhatt, DL Lincoff, AM Moliterno, DJ Brener, SJ Wolski, KE Topol, EJ
Citation: Dp. Chew et al., Optimal activated clotting time during percutaneous coronary intervention - Response, CIRCULATION, 104(15), 2001, pp. E83-E84
Clopidogrel versus aspirin after cardiac surgery - Response
Authors: Bhatt, DL Chew, DP Topol, EJ Hirsch, AT Hacke, W Ringleb, PA
Citation: Dl. Bhatt et al., Clopidogrel versus aspirin after cardiac surgery - Response, CIRCULATION, 104(13), 2001, pp. E76-E76
Defining the optimal activated clotting time during percutaneous coronary intervention - Aggregate results from 6 randomized, controlled trials
Authors: Chew, DP Bhatt, DL Lincoff, AM Moliterno, DJ Brener, SJ Wolski, KE Topol, EJ
Citation: Dp. Chew et al., Defining the optimal activated clotting time during percutaneous coronary intervention - Aggregate results from 6 randomized, controlled trials, CIRCULATION, 103(7), 2001, pp. 961-966
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
Authors: Bhatt, DL Chew, DP Hirsch, AT Ringleb, PA Hacke, W Topol, EJ
Citation: Dl. Bhatt et al., Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery, CIRCULATION, 103(3), 2001, pp. 363-368
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists -A meta-analysis of phase III multicenter randomized trials
Authors: Chew, DP Bhatt, DL Sapp, S Topol, EJ
Citation: Dp. Chew et al., Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists -A meta-analysis of phase III multicenter randomized trials, CIRCULATION, 103(2), 2001, pp. 201-206
Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting
Authors: Mukherjee, D Bhatt, DL Robbins, M Roffi, M Cho, L Reginelli, J Bajzer, C Navarro, F Yadav, JS
Citation: D. Mukherjee et al., Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting, AM J CARD, 88(9), 2001, pp. 1064
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein
Authors: Chew, DP Bhatt, DL Robbins, MA Mukherjee, D Roffi, M Schneider, JP Topol, EJ Ellis, SG
Citation: Dp. Chew et al., Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein, AM J CARD, 88(6), 2001, pp. 672-674
Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularisation
Authors: Mukherjee, D Comella, K Bhatt, DL Roe, MT Patel, V Ellis, SG
Citation: D. Mukherjee et al., Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularisation, AM HEART J, 142(1), 2001, pp. 72-74
Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularisation: Pooled analysis from EPIC, EPILOG, and EPISTENT
Authors: Cho, L Bhatt, DL Wolski, K Lincoff, M Topol, EJ Moliterno, D
Citation: L. Cho et al., Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularisation: Pooled analysis from EPIC, EPILOG, and EPISTENT, AM HEART J, 141(4), 2001, pp. 599-602
Embolization as a pathological mechanism
Authors: Bhatt, DL Topol, EJ
Citation: Dl. Bhatt et Ej. Topol, Embolization as a pathological mechanism, ACUTE CORONARY SYNDROMES, SECOND EDITION, 2001, pp. 79-110
Optimizing percutaneous coronary revascularization in diabetic women: Analysis from the EPISTENT trial
Authors: Cho, L Marso, SP Bhatt, DL Topol, EJ
Citation: L. Cho et al., Optimizing percutaneous coronary revascularization in diabetic women: Analysis from the EPISTENT trial, J WOMEN H G, 9(7), 2000, pp. 741-746
Update on clinical trials of antiplatelet therapy for cerebrovascular diseases
Authors: Bhatt, DL Kapadia, SR Yadav, JS Topol, EJ
Citation: Dl. Bhatt et al., Update on clinical trials of antiplatelet therapy for cerebrovascular diseases, CEREB DIS, 10, 2000, pp. 34-40
Abciximab reduces mortality in diabetics following percutaneous coronary intervention
Authors: Bhatt, DL Marso, SP Lincoff, AM Wolski, KE Ellis, SG Topol, EJ
Citation: Dl. Bhatt et al., Abciximab reduces mortality in diabetics following percutaneous coronary intervention, J AM COL C, 35(4), 2000, pp. 922-928
Glycoprotein inhibitors and fibrinolysis in myocardial infarction - Reply
Authors: Bhatt, DL Topol, EJ
Citation: Dl. Bhatt et Ej. Topol, Glycoprotein inhibitors and fibrinolysis in myocardial infarction - Reply, J AM MED A, 284(24), 2000, pp. 3124-3125
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
Authors: Bhatt, DL Topol, EJ
Citation: Dl. Bhatt et Ej. Topol, Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, J AM MED A, 284(12), 2000, pp. 1549-1558
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease
Authors: Bhatt, DL Topol, EJ
Citation: Dl. Bhatt et Ej. Topol, Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease, MED CLIN NA, 84(1), 2000, pp. 163
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting
Authors: Marso, SP Bhatt, DL Roe, MT Houghtaling, PL Labinaz, M Kleiman, NS Dyke, C Simmoons, ML Califf, RM Harrington, RA Topol, EJ
Citation: Sp. Marso et al., Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting, CIRCULATION, 102(24), 2000, pp. 2952-2958
Is the corrected TIMI frame count an independent predictor of adverse outcome?
Authors: Bhatt, DL Ellis, SG
Citation: Dl. Bhatt et Sg. Ellis, Is the corrected TIMI frame count an independent predictor of adverse outcome?, CIRCULATION, 102(2), 2000, pp. E19-E19
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease
Authors: Roe, MT Harrington, RA Prosper, DM Pieper, KS Bhatt, DL Lincoff, AM Simoons, ML Akkerhuis, M Ohman, EM Kitt, MM Vahanian, A Ruzyllo, W Karsch, K Califf, RM Topol, EJ
Citation: Mt. Roe et al., Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease, CIRCULATION, 102(10), 2000, pp. 1101-1106
Risultati: 1-25 | 26-32